Differential effects of eicosapentaenoic and docosahexaenoic acids upon oxidant-stimulated release and uptake of arachidonic acid in human lymphoma U937 cells

Pharmacological Research

Volumn 52, Issue 2, 2005, Pages 183-191

  Obajimi, Oluwakemi ^a   Black, Kenneth D ^a   MacDonald, Donald J ^b   Boyle, Rose M ^b   Glen, Iain ^c   Ross, Brian M ^d  

^a SCOTTISH MARINE INSTITUTE   (United Kingdom)

^b NHS Greater Glasgow and Clyde Clinical Biochemistry Service   (United Kingdom)

^c UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^d NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Arachidonic acid; Deacylation; Docosahexaenoic acid; Eicosapentaenoic acid; Lipid dysfunction; Lipid peroxidation; Polyunsaturated fatty acids (PUFAs); Reacylation; Schizophrenia; U937

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; OLEIC ACID; STEARIC ACID; TERT BUTYL HYDROPEROXIDE; TRITIUM;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RELEASE; DRUG UPTAKE; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL LINE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FERROUS COMPOUNDS; HUMANS; LIPID PEROXIDATION; PHOSPHOLIPASES A; TERT-BUTYLHYDROPEROXIDE; U937 CELLS;

EID: 20444480501     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.02.024     Document Type: Article

References (46)

1. T.A. Mori, and L.J. Beilin Omega-3 fatty acids and inflammation Curr Atheroscler Rep 6 2004 461 467
2. D.F. Horrobin A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E) Prog Drug Res 59 2002 171 199
3. M. Peet, J. Brind, C.N. Ramchand, S. Shah, and G.K. Vankar Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia Schizophr Res 49 2001 243 251
4. M. Peet, and D.F. Horrobin A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms J Psychiatr Res 36 2002 7 18
5. R. Emsley, C. Myburgh, P. Oosthuizen, and S.J. van Rensburg Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia Am J Psychiatry 159 2002 1596 1598
6. B. Nemets, Z. Stahl, and R.H. Belmaker Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder Am J Psychiatry 159 2002 477 479
7. M. Peet, and D.F. Horrobin A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs Arch Gen Psychiatry 59 2002 913 919
8. K.P. Su, S.Y. Huang, C.C. Chiu, and W.W. Shen Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial Eur Neuropsychopharmacol 13 2003 267 271
9. A.J. Richardson, and B.K. Puri A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties Prog Neuropsychopharmacol Biol Psychiatry 26 2002 233 239
10. L. Stevens, W. Zhang, L. Peck, T. Kuczek, N. Grevstad, and A. Mahon EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors Lipids 38 2003 1007 1021
11. W.S. Fenton, F. Dickerson, J. Boronow, J.R. Hibbeln, and M. Knable A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia Am J Psychiatry 158 2001 2071 2074
12. L.B. Marangell, J.M. Martinez, H.A. Zboyan, H. Chong, and L.J. Puryear Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study Depress Anxiety 19 2004 20 23
13. M. Peet, R.W. Edwards, and D.F. Horrobin N-3 fatty acids in the treatment of depression M. Peet I. Glen D.F. Horrobin Phospholipid spectrum disorders in psychiatry and neurology 2nd ed. 2003 Marius Press Carnforth 463 468
14. L.B. Marangell, J.M. Martinez, H.A. Zboyan, B. Kertz, H.F. Kim, and L.J. Puryear A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression Am J Psychiatry 160 2003 996 998
15. T. Ringbom, U. Huss, A. Stenholm, S. Flock, L. Skattebol, and P. Perera Cox-2 inhibitory effects of naturally occurring and modified fatty acids J Nat Prod 64 2001 745 749
16. 2 from human epidermis Biochem Soc Trans 19 1991 91
17. 2 isoforms: a perspective Cell Signal 15 2003 637 665
18. 2 Biochim Biophys Acta 1300 1996 197 202
19. J. Covault, H. Pettinati, D. Moak, T. Mueller, and H.R. Kranzler Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema Am J Med Genet 127B 2004 42 47
20. E.A. Emken, R.O. Adlof, S.M. Duval, and G.J. Nelson Effect of dietary docosahexaenoic acid on desaturation and uptake in vivo of isotope-labeled oleic, linoleic, and linolenic acids by male subjects Lipids 34 1999 785 791
21. A.I.M. Glen, and B.M. Ross Prostaglandins and eicosanoids in mental illness P. Curtis-Prior The eicosanoids 2004 Wiley Chichester 493 498
22. M. Maes, A. Christophe, J. Delanghe, C. Altamura, H. Neels, and H.Y. Meltzer Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients Psychiatry Res 85 1999 275 291
23. M. Peet, B. Murphy, J. Shay, and D. Horrobin Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients Biol Psychiatry 43 1998 315 319
24. N. Frasure-Smith, F. Lesperance, and P. Julien Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes Biol Psychiatry 55 2004 891 896
25. 2 Arch Gen Psychiatry 54 1997 487 494
26. W.F. Gattaz, M. Kollisch, T. Thuren, J.A. Virtanen, and P.K. Kinnunen Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy Biol Psychiatry 22 1987 421 426
27. M.M. Khan, D.R. Evans, V. Gunna, R.E. Scheffer, V.V. Parikh, and S.P. Mahadik Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics Schizophr Res 58 2002 1 10
28. D.F. Horrobin, K. Jenkins, C.N. Bennett, and W.W. Christie Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding Prostaglandins Leukot Essent Fatty Acids 66 2002 83 90
29. R. Maclean, P.E. Ward, I. Glen, S.J. Roberts, and B.M. Ross On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis Prog Neuropsychopharmacol Biol Psychiatry 27 2003 927 933
30. B.M. Ross, B. Hughes, S. Turenne, M. Seeman, and J.J. Warsh Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry Eur Neuropsychopharmacol 14 2004 191 197
31. B.M. Ross, P. Ward, and I. Glen Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder J Affect Disord 82 2004 285 290
32. H. Obermeier, N. Hrboticky, and A. Sellmayer Differential effects of polyunsaturated fatty acids on cell growth and differentiation of premonocytic U937 cells Biochim Biophys Acta 1266 1995 179 185
33. 2+-sensitive cytosolic phospholipase A2 is a 100-kDa protein in human monoblast U937 cells J Biol Chem 266 1991 5268 5272
34. 2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling Biochem J 15 364 2002 695 702
35. 2+ in the presence of xylenol orange: comparision with the TBA assay and an iodometric method Lipids 26 1991 853 856
36. 2 using ELISA Prostaglandins Leukot Essent Fatty Acids 70 2004 377 381
37. M. Alberghina, G. Lupo, C.D. Anfuso, and S.H. el Ghonemy Lipid peroxidation inhibits acyl-CoA:-1-acyl-sn-glycero-3-phosphocholine O-acyltransferase but not CTP: phosphocholine cytidylyltransferase activity in rat brain membranes Neurochem Int 26 1995 477 487
38. A. Mishra, A. Chaudhary, and S. Sethi Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway Arterioscler Thromb Vac Biol 24 2004 1621 1627
39. S. Sethi, O. Ziouzenkova, H. Ni, D.D. Wagner, J. Plutzky, and T.N. Mayadas Oxidised omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions though activation of PPAR alpha Blood 100 2002 1340 1346
40. F. Visioli, C. Colombo, and C. Galli Oxidation of individual fatty acids yields different profiles of oxidation markers Biochem Biophys Res Commun 245 1998 487 489
41. C. Mazière, F. Dantin, M.-A. Conte, J. Degonville, D. Ali, and F. Dubois Polyunsaturated fatty acid enrischment enhances endothelial cell-induced low-density-lipoprotein peroxidation Biochem J 336 1998 57 62
42. R. De Caterina, M. Spieker, G. Solaini, G. Basta, F. Bosetti, and P. Libby The inhibition of endothelial activation by unsaturated fatty acids Lipids 34 1999 S191 S194
43. T.A. Mori, R.J. Woodman, V. Burke, I.B. Puddey, K.D. Croft, and L.J. Beilin Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects Free Radic Biol Med 25 2003 772 781
44. J.G. Bell, E.E. MacKinlay, J.R. Dick, D.J. MacDonald, R.M. Boyle, and A.C. Glen Essential fatty acids and phospholipase A2 in autistic spectrum disorders Prostaglandins Leukot Essent Fatty Acids 71 2004 201 204
45. C.H. Lee, P. Olson, and R.M. Evans Minireview: lipid metabolism, metabolic diseases and peroxisome proliferator-activated receptors Endocrinology 144 2003 2201 2207
46. L. Madsen, L. Froyland, E. Dyroy, K. Helland, and R.K. Berge Docosahexaenoic and eicosapentaenoic acids are differently metabolized in rat liver during mitochondria and peroxisome proliferation J Lipid Res 39 1998 583 593